Cantargia

Edison Investment Research has terminated coverage on Cantargia (CANTA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Thematics

Latest

Stock of the month – March

Edison and Aquis: Insights from Aquis class of 2025 celebration

Edison explains: AI for insurance brokers and platforms – threat or opportunity?

Audiovisual

Latest

Take on trusts – March 2026

YXT.com – executive interview

Greggs – executive interview

About Edison

Corporates

Investors

Careers

Cantargia (OMX: CANTA)

Latest Insights

Cantargia (OMX: CANTA) granted new US patent

Cantargia (OMX: CANTA): CAN10 programme acquired by Otsuka

Cantargia (OMX: CANTA) – Nadunolimab receives FDA Fast Track designation

Cantargia (OMX: CANTA) enrols first patient in leukaemia study

Sector

Equity Analyst

Key Management

Cantargia — CAN04 progressing on all fronts

Cantargia — Useful insights from CANOPY-1 data

Cantargia – executive interview

Cantargia: Edison Open House Healthcare 2022

Cantargia — ‘Post-Novartis’ era has begun

Cantargia – executive interview

Cantargia — Sentiment affected, but fundamentals robust

Cantargia – executive interview

Cantargia — Novartis’s CANOPY-2 trial disappoints

Cantargia – Edison Open House interview

Cantargia — Buoyant on CANFOUR and CANOPY interims

Cantargia — Great equity story underpins large share issue

Executive interview – Cantargia

Cantargia — Excellent end to the year

Cantargia — CANFOUR study on track, US trial preparations

Cantargia — Full Phase I data presented at ASCO

Cantargia — Signs of growing interest in IL-1 pathway targets

Executive interview – Cantargia

Cantargia — Nidanilimab transitioning to Phase IIa

Cantargia — CANFOUR interim Phase I presented at ESMO

Cantargia — Phase IIa set to start in Q418

Cantargia — Tackling tumour promoting inflammation